Predict your next investment

Endowment
mssm.edu

See what CB Insights has to offer

Partners & Customers

1

About Mount Sinai School of Medicine

Mount Sinai School of Medicine is an endowment based out of New York, New York.

Mount Sinai School of Medicine Headquarter Location

1 Gustave L. Levy Place

New York, New York, 10029,

United States

(212)241-6500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Mount Sinai School of Medicine News

Diminished waveforms on EKGs of hospitalized patients can help predict worsening health, death

Sep 25, 2021

Specific and dynamic changes on electrocardiograms (EKGs) of hospitalized patients with COVID-19 or influenza can help predict a timeframe for worsening health and death, according to a new Mount Sinai study. The work, published in the September 24 online issue of the American Journal of Cardiology, shows that shrinking waveforms on these tests can be used to help better identify high-risk patients and provide them more aggressive monitoring and treatment. "Our study shows diminished waveforms on EKGs over the course of COVID-19 illness can be an important tool for health care workers caring for these patients, allowing them to catch rapid clinical changes over their hospital stay and intervene more quickly. With COVID-19 cases and hospitalizations continuing to rise again, EKGs may be helpful for hospitals to use when caring for these patients before their condition gets dramatically worse," says senior author Joshua Lampert, MD, Cardiac Electrophysiology fellow at The Mount Sinai Hospital. This is particularly useful in overwhelmed systems, as there is no wait for blood work to return and this test can be performed by the majority of health care personnel. Additionally, the EKG can be done at the time of other bedside patient care, eliminating the potential exposure of another health care worker to COVID-19." Joshua Lampert, MD, Study Senior Author, Cardiac Electrophysiology Fellow, The Mount Sinai Hospital. An EKG is a noninvasive test that records the electrical activity of the heart. It is widely used for diagnosing cardiovascular disease and arrhythmia, or abnormal heart rhythm. Small patches called electrodes are placed on the arms, legs, and chest, and connected by wires to a machine that turns the heart's electrical signals into wavy lines. Researchers did a retrospective analysis of EKGs on 140 patients hospitalized with COVID-19 across the Mount Sinai Health System in New York City between March 7 and April 12, 2020, and compared them with 281 EKGs from patients with laboratory-confirmed influenza A or influenza B admitted to The Mount Sinai Hospital between January 2, 2017, and January 5, 2020. The researchers looked at three EKG time points for each patient: a baseline scan done within a year prior to COVID-19 or influenza hospitalization (and available in Mount Sinai's records), a scan taken at hospital admission, and follow-up EKGs performed during hospitalization. Related Stories They manually measured QRS waveform height-;a measure of the electrical activity of the ventricles, the major chambers of the heart-; on all electrocardiograms; changes in this electrical activity could be a sign that the ventricles are failing. The researchers analyzed follow-up EKGs after hospital admission and analyzed changes in the waveforms according to a set of criteria they developed called LoQRS amplitude (LoQRS) to identify shrinkage of the electrical signal on the EKG. LoQRS was defined by QRS amplitude measuring less than 5mm measured from the arms and legs or less than 10mm when measured on the chest wall as well as a relative reduction in waveform height in either location by at least 50 percent. Fifty-two COVID-19 patients in the study did not survive, and the analysis shows 74 percent of those patients had LoQRS. Their EKG QRS waveforms became smaller roughly 5.3 days into their hospital admission and they died approximately two days after the first abnormal EKG was found. Out of the 281 influenza patients studied, LoQRS was identified in 11 percent of them. Seventeen influenza patients died, and LoQRS was present in 39 percent of these cases. Influenza patients met LoQRS criteria a median of 55 days into their hospital admission, and the median time to death was six days from when LoQRS was identified. Overall, these results show influenza patients followed a less virulent course of illness when compared to COVID-19 patients. "When it comes to caring for COVID-19 patients, our findings suggest it may be beneficial not only for health care providers to check an EKG when the patient first arrives at the hospital, but also follow-up EKGs during their hospital stay to assess for LoQRS, particularly if the patient has not made profound clinical progress. If LoQRS is present, the team may want to consider escalating medical therapy or transferring the patient to a highly monitored setting such as an intensive care unit (ICU) in anticipation of declining health," adds Dr. Lampert. Source:

Mount Sinai School of Medicine Partners & Customers

1 Partners and customers

Mount Sinai School of Medicine has 1 strategic partners and customers. Mount Sinai School of Medicine recently partnered with Baylor Scott & White Health on October 10, 2007.

Date

Type

Business Partner

Country

News Snippet

Sources

10/17/2007

Partner

Baylor Scott & White Health

United States

Researchers to Investigate Ways to Better Diagnose Autoimmune Disorders. Baylor Research Institute To Collaborate With Mount Sinai School Of Medicine To Develop Therapeutic Cancer Vaccines.

Officials with Baylor and the Mount Sinai School of Medicine announced today that the institutions are collaborating to develop therapeutic cancer vaccines for patients with lymphoma and myeloma , both cancers that affect the immune system .

1

Date

10/17/2007

Type

Partner

Business Partner

Baylor Scott & White Health

Country

United States

News Snippet

Researchers to Investigate Ways to Better Diagnose Autoimmune Disorders. Baylor Research Institute To Collaborate With Mount Sinai School Of Medicine To Develop Therapeutic Cancer Vaccines.

Officials with Baylor and the Mount Sinai School of Medicine announced today that the institutions are collaborating to develop therapeutic cancer vaccines for patients with lymphoma and myeloma , both cancers that affect the immune system .

Sources

1

Mount Sinai School of Medicine Team

6 Team Members

Mount Sinai School of Medicine has 6 team members, including current Chief Executive Officer, President, Kenneth L Davis.

Name

Work History

Title

Status

Kenneth L Davis

Chief Executive Officer, President

Current

David L Reich

President, Chief Operating Officer

Current

Jeffrey S

Chief Operating Officer, Executive Vice President

Current

Larry H. Hollier

President

Former

Dorie Klissas

Chief Marketing Officer

Former

Name

Kenneth L Davis

David L Reich

Jeffrey S

Larry H. Hollier

Dorie Klissas

Work History

Title

Chief Executive Officer, President

President, Chief Operating Officer

Chief Operating Officer, Executive Vice President

President

Chief Marketing Officer

Status

Current

Current

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.